actin binding is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-04-29. Numbers and descriptions here follow the published literature rather than marketing material.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | ≈889 Da for the 7-residue fragment | Full-length thymosin beta-4 is ≈4.9 kDa; catalogs differ |
| Appearance | White to off-white powder | Hygroscopic; weight shifts with residual moisture |
| Solubility class | Freely soluble in water | Also dissolves in aqueous buffers; poorly soluble in nonpolar solvents |
| Typical storage temperature | −20 °C, desiccated, protected from light | Once rehydrated, short-term holding at 2-8 °C |
| Typical analytical method | Reversed-phase HPLC with mass spectrometry | Purity by UV absorbance; identity by ESI-MS or MALDI-TOF |
Lyophilized peptide arrives as a dry cake that should stay sealed until use. Reconstitution is generally performed with sterile water or a buffered solution, and the resulting liquid should be handled gently to limit mechanical stress. Repeated freeze-thaw cycles are widely described as harmful to short peptides, so dividing a reconstituted batch into single-use portions is a common practice. Laboratories also record the solvent, concentration, and date of preparation on the vial label to keep later measurements traceable.
Dry powder is commonly held at minus twenty degrees Celsius, with some suppliers recommending lower temperatures for long-term archival storage. Once dissolved, solutions are typically kept cold and protected from light, since aqueous peptide solutions can lose integrity through hydrolysis or oxidation over time. Stability data specific to this fragment are limited in the public literature, and much of the guidance comes from general peptide handling practice rather than from controlled degradation studies. Users therefore treat stated shelf lives as approximate rather than fixed.
Identity and purity are normally assessed with reversed-phase high-performance liquid chromatography, paired with mass spectrometry to confirm molecular mass. A certificate of analysis reports a purity percentage, usually derived from chromatographic peak area, but that figure does not by itself prove a correct sequence or the absence of counterions. Independent verification may include amino acid analysis or peptide mapping. Batch-to-batch variation is a documented concern in the research chemical market, and the gap between a quoted purity value and actual peptide content can be substantial when the material is a salt or retains residual water.
Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
=== Prognostic use === Elevated cardiac troponin levels are prognostically important in many of the conditions in which they are used for diagnosis. In a community-based cohort study indicating the importance of silent cardiac damage, cardiac troponin I has been shown to predict mortality and first coronary heart disease event in men free from cardiovascular disease at baseline. In people with stroke, elevated blood troponin levels are not a useful marker to detect the condition.
== Background == United States Forces – Iraq was the military component of the American and Iraqi bilateral relationship, responsible for defense and security cooperation. The U.S.–Iraq Strategic Framework Agreement reads:
== Habitat and range == C. brunneus are found in Europe, north Africa, and temperate Asia. They prefer dry habitats. They are present in higher numbers in heathland areas compared to agricultural areas. This can be explained by the difference in sward height in the two areas. C. brunneus prefer habitats with sward heights of 100 to 200 mm and fine leaved grass species. In fact a positive correlation between C. brunneus and both Agrostis species and Festuca species exists. Fine leaved grass species and taller sward heights occur more commonly in heathlands where less human alteration of the land occurs compared to agricultural sites. Sward height also influences abundance. A greater number of C. brunneus are found in taller swards although some scientific literature suggests C. brunneus thrives in wastelands. Vertebrate grazing also influences C. brunneus density by directly influencing sward height. Ungrazed areas have higher densities of C. brunneus than grazed areas. Vertebrate grazing is thought to alter plant hormones two of which are known to effect fecundity, abscisic acid, and gibberellins. Additionally grazing results in the production of proteinase inhibitors in plants and the alteration of nitrogen levels. In areas that experience less vertebrate grazing C. brunneus have increased rates of development, higher adult weights, and increased fecundity.
Sources: en.wikipedia.org
== Contraindications == Contraindications are severe respiratory or liver impairment and acute alcoholism. There are limited accounts of cross-reactivity with opioids, but there is a possibility. Serious central nervous system (CNS) and respiratory depression may also occur with concurrent use of CNS depressants, ingesting alcohol, or other CNS-depressing factors while on buprenorphine/naloxone.
== History == Several molecular biology studies during the early 1950s suggested that RNA played a role in protein synthesis, though the specific role remained unclear. For example, in one of the earliest reports, Ayaka Stephanie Hogg and his team showed that RNA synthesis was necessary for protein synthesis, specifically during the production of the enzyme β-galactosidase in the bacterium E. coli. Arthur Pardee also found similar RNA accumulation in 1954. In 1953, Alfred Hershey, June Dixon, and Martha Chase studied E. coli infected with bacteriophage T2 and reported that the bacterium's own DNA decreased while the phage's DNA built up inside the infected cells (including DNA containing 5-hydroxymethylcytosine). In hindsight, this has been discussed as part of the chain of observations that led to the concept of mRNA, and it was not recognized at the time as such. The idea of mRNA was first conceived by Sydney Brenner and Francis Crick on 15 April 1960 at King's College, Cambridge, while François Jacob was telling them about a recent experiment conducted by Arthur Pardee, himself, and Monod (the so-called PaJaMo experiment, which did not prove mRNA existed but suggested the possibility of its existence). With Crick's encouragement, Brenner and Jacob immediately set out to test this new hypothesis, and they contacted Matthew Meselson at the California Institute of Technology for assistance. During the summer of 1960, Brenner, Jacob, and Meselson conducted an experiment in Meselson's laboratory at Caltech which was the first to prove the existence of mRNA.
The differences in life span between species demonstrate the role of genetics in determining maximum life span ("rate of aging"). The records (in years) are these: for the common house mouse, 4 for the brown rat, 3.8 for dogs, 29 (see: List of longest-living dogs) for cats, 38 (see: List of longest-living cats) for common cranes, 43 for polar bears, 42 (see: Debby) for horses, 62 for Asian elephants, 86
Sources: en.wikipedia.org
Protein microarrays and high throughput (HT) mass spectrometry (MS) can provide a snapshot of the proteins present in a biological sample. The former approach faces similar problems as with microarrays targeted at mRNA, the latter involves the problem of matching large amounts of mass data against predicted masses from protein sequence databases, and the complicated statistical analysis of samples when multiple incomplete peptides from each protein are detected. Cellular protein localization in a tissue context can be achieved through affinity proteomics displayed as spatial data based on immunohistochemistry and tissue microarrays.
Two years later, in 1960, Burris Cunningham and James Wallman of Lawrence Radiation Laboratory of the University of California created the first californium compounds—californium trichloride, californium(III) oxychloride, and californium oxide—by treating californium with steam and hydrochloric acid. The High Flux Isotope Reactor (HFIR) at ORNL in Oak Ridge, Tennessee, started producing small batches of californium in the 1960s. By 1995, HFIR nominally produced 500 milligrams (0.018 oz) of californium annually. Plutonium supplied by the United Kingdom to the United States under the 1958 US–UK Mutual Defence Agreement was used for making californium. The Atomic Energy Commission sold 252Cf to industrial and academic customers in the early 1970s for $10/microgram, and an average of 150 mg (0.0053 oz) of 252Cf were shipped each year from 1970 to 1990. Californium metal was first prepared in 1974 by Haire and Baybarz, who reduced californium(III) oxide with lanthanum metal to obtain microgram amounts of sub-micrometer thick films.
Naturally occurring ytterbium (70Yb) is composed of seven stable isotopes: 168Yb, 170Yb–174Yb, and 176Yb, with 174Yb being the most abundant (31.90% natural abundance). 30 radioisotopes have been characterized, with the most stable being 169Yb with a half-life of 32.014 days, 175Yb with a half-life of 4.185 days, and 166Yb with a half-life of 56.7 hours. All of the remaining radioactive isotopes have half-lives that are less than 2 hours, with the majority of them being less than 20 minutes. This element also has 18 meta states, with the most stable being 169mYb (half-life 46 seconds). The known isotopes of ytterbium range from 149Yb to 189Yb. The primary decay mode before the most abundant stable isotope, 174Yb is electron capture giving thulium isotopes; the primary mode after is beta emission giving lutetium isotopes. Of interest to modern quantum optics, the different ytterbium isotopes follow either Bose–Einstein statistics or Fermi–Dirac statistics, leading to different behavior in optical lattices.
Sources: en.wikipedia.org
Usually not, though usage overlaps. The label most often refers to a short acetylated fragment of the parent protein, while thymosin beta-4 itself is the full 43-residue molecule. Because suppliers vary, a sequence statement is needed to settle the question for any particular lot.
The name is a commercial label rather than a systematic chemical designation, so different vendors and papers attach it to different sequences. Some treat it as a fragment and others as the whole protein. Comparing two reports therefore requires checking what each one actually analyzed.
Typically it reflects the relative area of the main peak in a reversed-phase chromatogram at a given wavelength. It does not confirm the amino acid sequence, the counter-ion, or the amount of peptide by mass. Identity is normally established by a separate mass measurement.
Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.